Developing better treatments for patients in need

At MyMD, we’re partnering with internationally renowned scientists and academics to validate the promise of our drug candidates as anti-inflammatory and anti-ageing technologies that treat the causes of disease and decline rather than simply focusing on the symptoms. We are working to rapidly advance MYMD-1® and Supera-CBD in clinical trials while identifying and validating additional novel targets.

We recently partnered with The Bascom Palmer Eye Institute, the number one eye hospital in the US, to preclinically evaluate MYMD-1® as a potentially safe, effective, and easily administrable treatment for traumatic optic neuropathy (TON). In addition, we have had collaborations with highly regarded institutions including the Johns Hopkins University School of Medicine which recently resulted in publication of a preclinical study in Journal of Gerontology: Biological Sciences.

Key findings on MYMD-1® 

MYMD-1® regulates TNF-alpha, an essential first line responder to acute infection  

Our research shows that, at only about 146 Daltons, MYMD-1® is the first oral TNF-alpha regulator capable of crossing the blood-brain barrier, which could enable it to address brain-related diseases. 

Unlike other therapies, MYMD-1® selectively blocks TNF-alpha when it becomes overactivated in autoimmune diseases and cytokine storms, mitigating the risk of life-threatening infections. Additionally, MYMD-1® selectively inhibits TNF-alpha production in lymphocytes but not in macrophages and as a result does not block the ability of the immune system to fight bacterial and viral infections.

Clinical trials are underway 

MyMD is currently conducting a Phase 2 clinical trial of MYMD-1® in Sarcopenia (aging-related frailty) and expects efficacy data by the end of 2022. In addition, we expect to advance MYMD-1® into phase 2 clinical trials for other potential indications including rheumatoid arthritis, Hashimoto’s thyroiditis, and additional programs. We will also execute studies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, chronic pain, and anxiety disorders.

For patients or physicians interested in learning more about the studies, please visit

Featured publications on MyMD new biotechnology research

MyMD drug candidates have been the subject of peer-reviewed research publications from distinguished institutions.

The Journal of Immunology

MYMD-1®, a Novel Immunometabolic Regulator, Ameliorates Autoimmune Thyroiditis via Suppression of Th1 Responses and TNF-α Release

Read the Article

The Journal of Neuroimmunology

MYMD-1®, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis

Read the Article

Featured research from MyMD on age-related and immunometabolic diseases

MyMD researchers and collaborators have developed research resources to highlight the drug candidates and their therapeutic potential.


The white paper from MyMD details aging and sarcopenia as well as current therapies.

View the whitepaper


Learn more about the structure of Supera-CBD

Download the resource


See the poster presented at the 3rd Annual Neuroimmunology Drug Development Conference

Download the presentation
  • This field is for validation purposes and should be left unchanged.